Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
about
Emerging drugs and vaccines for candidemiaCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsIsavuconazole: A New Broad-Spectrum Triazole Antifungal AgentProphylactic Measures During Induction for Acute Myeloid Leukemia.Antifungal clinical trials and guidelines: what we know and do not knowPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelSpecial considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisPharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis?Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsFungi: the neglected allergenic sources.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Isavuconazole treatment of a patient with disseminated mucormycosis.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Systemic Antifungal Agents: Current Status and Projected Future Developments.New facets of antifungal therapy.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
P2860
Q26828993-C2BB76A9-8001-4BDF-892B-BA5E75DB4F0AQ26863344-1635E98A-6B4B-4E20-8647-0AC3ADB62EA7Q28067726-C4F4DE9F-2B75-40BE-80C6-8B74036BEAF2Q28082019-FD7540AB-699A-410F-8FE7-42BACE032D6BQ30235496-E16C53DC-6C14-4DCF-9FA1-D8BC4F6C5BA1Q34400255-E9ED760C-F03D-43D9-9021-E478A42BD541Q34532546-BD34FEFD-4E5B-4BA7-AAF1-2CB678FD3F87Q35385554-F2362A1E-562B-46E3-A140-00D7E4E86FFEQ36396166-842DFFA1-CA8C-4382-B875-2FBDDFEC547FQ36439102-D4717476-6592-447D-83E2-B14182DA31EFQ36887855-A0A128E7-BC4C-4A20-A4E1-5BDD216B7365Q37036173-46A28934-92EB-4E37-8865-E1E26EC30E09Q37125086-26315625-5F04-4345-ABC8-4643D94BCEC9Q37463387-D0A272F6-B2D6-4F6F-A434-6FEE02DF70AFQ38159688-64073FB4-1FD0-4D92-BBCA-E4C6E9569606Q38167038-CC708657-F21A-42BB-9012-4C1204D6D6FCQ38285488-E6E884DB-7221-45C2-A482-C066793CC46DQ38322367-D6582EF8-6A1C-41CF-990B-DD75AE4406C8Q38534865-36310C6E-C8E2-45BC-B585-DCEB64ED3138Q38796140-D7F1718F-EF84-4CCB-B74E-7E14CDD42A7BQ38797864-17DE4D4A-7435-42A3-93E0-60B6D3B57563Q38939506-E8F0925E-5B98-4C77-A762-206F49CBDE5BQ39003715-6FCEE2A9-B588-4D18-8B21-78C09C3110ADQ39364669-1E9B7A45-7749-4BCA-84A2-2AA7CC700852Q40140001-62AD834B-D9BA-473E-9D72-66FD8B15FF15Q54214603-648A5916-28F9-49CF-881A-DB578BCB5383
P2860
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Evaluation of the pharmacokine ...... of invasive fungal infections.
@en
type
label
Evaluation of the pharmacokine ...... of invasive fungal infections.
@en
prefLabel
Evaluation of the pharmacokine ...... of invasive fungal infections.
@en
P2860
P1476
Evaluation of the pharmacokine ...... of invasive fungal infections.
@en
P2093
Joanne Livermore
P2860
P304
P356
10.1517/17425255.2012.683859
P407
P50
P577
2012-04-25T00:00:00Z